applepharmaceutical@gmail.com
drugs

PRODUCT DETAILS

Brand Name : Kisqali
Composition : Ribociclib
Strength availability : 200mg
Manufactured by : Novartis Pharmaceuticals Ltd
Pack : Blister pack contains 21 tablets
for MORE INFORMATION !!!

Kisqali 200mg is an anti-cancer ("antineoplastic") chemotherapy drug. This medication is classified as a "cyclin-dependent kinase inhibitor."4 and 6 (CDK4/6).
Kisqali 200mg is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in the cells that cause cancer to grow.

INDICATION

Kisqali 200mg is indicated in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer

ADME

Absorption:
peak plasma concentration is 1-4 hr and steady state achieved is 8 days
Distribution:
Human serum protein bound is 70%
Metabolism:
primarily metabolised by hepatic through CYP3A4 in humans
Elimination:
Kisqali is excreted through feces 69% and urine 23%
Half -life is 32.6 hours.

DOSAGE

The usual dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days
The drug Kisqali can be administrated with or without food.
Overdose:
overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.

MECHANISM

Some proteins in the body results in cells to develop and divide. In ER positive (ER+), HER2 negative breast cancer, these proteins can turn into overactive and provoke breast cancer cells to develop. Ribociclib works by stopping these proteins, helping to inhibits the cancer cells growing and dividing.
When concomitant use with hormone treatmentwhichstops the effects of oestrogen on cancer cells, Ribociclibsupport to delay the growth of ER+, HER2 negative breast cancer.

PRECAUTION

Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation.
Avoid the combination use with tamoxifen due to increased QT prolongation.
In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.

DRUG INTERACTION

Interaction of Kisqali 200mg with strong CYP3A4 inhibitor will increased Ribociclib exposure in healthy subjects but this combination cannot be avoided, so reduce the dose of Kisqali to 400mg once daily Kisqali 200mg concomitant use with strong CYP3A4 inducers will decreased Ribociclib exposure in healthy subjects by 89% Co administration of midazolam with multiple doses of Kisqali will increased the midazolam exposure by 3.8-fold in healthy subjects.

CONTRAINDICATION

None

MISSED DOSE

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.

STORAGE

The drug Kisqali is store at 20℃ to 25℃

SIDE EFFECTS

• Decreased in blood counts
• Nausea and vomiting
• Increased liver enzymes
• Fatigue
• Diarrhea
• Hair loss
• Decreased kidney function
• Lack of appetite
• Rash
• Fever
• Itching
• Insomnia
• Urinary tract infection.

We'd Like to Hear From You!

PRESCRIPTION POLICY

1. myapplepharma.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. myapplepharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the myapplepharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. myapplepharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from myapplepharma.com.
6. At myapplepharma.com, a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.